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Summary
Ochratoxin A (OTA) is a nephro- and hepatotoxic mycotoxin pro-
duced by various species of the genera Aspergillus and Penicillium.
OTA is known to bind with high affinity to plasma proteins which
may have a substantial impact on its bioavailability and, thus, on
its toxicity. However, the underlying mechanisms of OTA-induced
cellular toxicity have not yet been fully elucidated. It has been
suggested that oxidative damage contributes to its cytotoxic effects.
Dietary antioxidants such as vitamin E and polyphenols may there-
fore counteract OTA-induced cell death. Furthermore, compounds
influencing the intracellular level of glutathione (L-gamma-glutamyl-
L-cysteinylglycine, GSH), the most abundant thiol antioxidant in
mammalian cells, may have an impact on OTA-induced cytotoxicity.
In this study we investigated the effects of serum concentrations as
well as different dietary antioxidants on the viability of OTA-exposed
liver (HepG2) cells. Additionally, we determined the intracellular
GSH-levels after incubation with OTA and N-acetylcysteine (NAC,
a precursor of GSH) or buthionine sulfoximine (BSO, an inhibitor
of gamma-glutamylcysteinyl synthetase). Incubation of human
hepatoma cells (HepG2) for 24 h with increasing concentrations of
OTA (0.25 - 50 µmol/l) in the presence of 0, 2.5, 5, or 10% foetal
calf serum (FCS) resulted in a dose-dependent decrease in cell
viability. Decreasing the serum concentrations in the cell culture
medium led to increased cell mortality. Pre-treatment for 24 h with
RRR-α-tocopherol (α-TOC), RRR-α-tocopherolphosphat (α-TOC-
P), epigallocatechin gallate (EGCG), quercetin (QUE), catechin
(CAT), and rosmarinic acid (ROSAC) at concentrations of 25, 50
and 100 µmol/l did not prevent OTA-induced toxicity. α-TOC-P,
EGCG, and QUE even amplified the cytototoxic effects of OTA in
HepG2. Supplementation with NAC and BSO in the presence of OTA
did not substantially change cell viability, although BSO treatment
resulted in depletion of cellular GSH. OTA treatment increased GSH
levels at concentrations of 50 and 100 nmol/l, but decreased cellular
GSH at the higher concentrations (250, 500, and 1000 nmol/l). The
decrease in cellular GSH concentrations was less pronounced than
for BSO. Our results indicate that the cytotoxicity of OTA in HepG2
cells, which is strongly dependent on the protein concentration in
the cell culture medium, can not be prevented by pre-incubation with
dietary antioxidants. Although cellular GSH levels are influenced
by OTA incubation, mechanisms other than oxidative stress are likely
to be involved in OTA-induced cell death in HepG2 cells.
Introduction
The mycotoxin ochratoxin A (OTA), mainly produced by Aspergillus
ochraceus and Penicillium verrucosum, is the most toxic of the three
known members of the ochratoxin family (ochratoxin A, B, and C).
OTA was discovered and its chemical structure described in 1965
(VAN DER MERWE et al., 1965). Chemically, OTA consists of a
dihydroisocumarin moiety joined by a peptide bond to 1-phenyl-
alanine (Fig. 1). OTA can be found in many foods and beverages,
e.g. cereal grains, coffee, and wine (FAZEKAS et al., 2002; STUDER-
ROHR et al., 1995; VAN EGMONT et al., 1994). Due to its ubiqui-
tous occurrence in foods, it is virtually impossible to completely
avoid ingestion of OTA. Both in animals and humans, a wide range
of toxic effects of OTA has been reported, including renal and hepatic
toxicity (BENDELE et al., 1985), genotoxicity (CREPPY et al., 1985;
BOSE and SINHA, 1994), neurotoxicity (MIKI et al., 1994; BRUININK
et al., 1998), and immunotoxicity (HARVEY et al., 1992; PETZINGER
and ZIEGLER, 2000). Severe human renal diseases, such as Endemic
Nephropathy (BEN), chronic interstitial nephritis and karyomegalic
interstitial nephritis, may be a result of continued exposure to OTA
(SIMON et al., 1996). Moreover, the International Agency for Research
on Cancer has classified OTA as a class 2B carcinogen (possible
human carcinogen) (IARC, 1991).
Fig. 1: Chemical structure of ochratoxin A
The toxicity of OTA is largely determined by its protein binding
properties. In blood, 99% of OTA is bound to serum proteins (mainly
albumin), which prolongs its systemic half-life, delays its elimination
and may, therefore, amplify its toxicity (CHU, 1971; CHU, 1974).
The exact mode of action of OTA toxicity is as yet unclear. The
toxicity of OTA has been explained by three major mechanisms: 1.
inhibition of protein synthesis via inhibition of phenylalanine-tRNA
synthetases (CREPPY et al., 1979; CREPPY et al., 1998), 2. inhibition
of mitochondrial function (MOORE and TRUELOVE, 1970; MEISNER,
and CHAN, 1974; WEI et al., 1985), and 3. generation of reactive
oxygen species (ROS) which may oxidise DNA, proteins, lipids, and
other macromolecules (RAHIMTULA et al., 1988; OMAR et al., 1990;
SCHAAF et al., 2002; DOMIJAN et al., 2005; KAMP et al., 2005).
Therefore, antioxidants may counteract OTA-induced cytotoxicity.
Recent studies have shown that supplementation with vitamin E or
several polyphenols partly diminished the toxic effects of OTA
(SCHAAF et al., 2002; BALDI et al., 2004; RENZULLI et al., 2004;
GUERRA et al., 2005). Furthermore, an involvement of the glutathione
(GSH) system in OTA cytotoxicity, has been suggested. GSH (γ-
glutamylcysteinylglycine) functions as a free radical scavenger, and
serves as a nucleophilic co-substrate for glutathione transferases
in the detoxification of xenobiotics. It has been shown that pre-
incubation with N-acetylcysteine (NAC), a precursor of GSH, com-
pletely prevented OTA-induced cell death in kidney (LLC-PK1) cells
(SCHAAF et al., 2002).
The objective of the present study was to assess the impact of serum
protein concentration in the cell culture medium and the effect of
dietary antioxidants on OTA-induced cytotoxicity in HepG2 cells.
Furthermore, we aimed at investigating whether modulation of
cellular GSH levels affects OTA-induced cytotoxicity in human liver
cells in culture.
Materials and methods
Cell culture and determination of OTA-cytotoxicity
The human hepatoblastoma derived cell line HepG2 was cultured in
RPMI medium supplemented with 10% FCS, 2 mmol/l glutamine,
100 IU/ml penicillin and 100 µg/ml streptomycin under standard
conditions (37°C, 5% CO2). Confluent cells were harvested by tryp-
sination and seeded at 1 x 105 cells per well in 24-well plates. The
medium was changed every 48 h.
In dose-response experiments, HepG2 cells were exposed to in-
creasing concentrations of OTA ranging from 0.25 - 50 µmol/l for
24 h. The FCS concentrations in the medium were 0, 2.5, 5 or 10%.
In a separate experiment, HepG2 cells were incubated with OTA at
concentrations of 10 - 1000 nmol/l to find out the highest non-toxic
OTA concentration under serum-free conditions. The cytotoxicity
of OTA was determined employing the neutral red (NR) assay
(VALACCHI et al., 2001). This test is based on the ability of viable
cells to incorporate NR in lysosomes which is photometrically
measured at 540 nm. Cell viability was expressed as percentage of
solvent-exposed control (0.1% methanol) survival. For each in-
cubation period, two independent experiments were performed in
triplicate (n = 6).
Pre-incubation with test substances
To study the potential protective effects of vitamin E and polyphenols
on OTA-induced cytotoxicity, cells were pre-treated with RRR-
α-tocopherol (α-TOC), RRR-α-tocopherolphosphate (α-TOC-P),
epigallocatechin gallate (EGCG), quercetin (QUE), catechin (CAT),
and rosmarinic acid (ROSAC) (Fig. 2) for 24 h at concentrations of
25, 50, and 100 µmol/l (non-toxic concentrations for HepG2 cells,
data not shown). 100 mmol/l stock solutions were prepared in
dimethyl sulfoxide (DMSO), ethanol or an acetic acid:ethanol mixture
(1:3) for the polyphenols, α-TOC and α-TOC-P, respectively. Stock
solutions were further diluted in culture medium containing 10%
FCS with a maximum solvent concentration of 0.1%.
Cells were washed twice with PBS and incubated for another 24 h
with 1, 5 or 15 µmol/l OTA in serum-free RPMI. Additionally, HepG2
were pre-incubated for 24 h with 0, 0.2, 0.5, 1, 2, or 4 mmol/l NAC
or 0, 5, 25, 50, 100, or 500 µmol/l BSO. BSO and NAC were pre-
pared as 100 mmol/l stock solutions in PBS. The pH of the NAC
stock solution was adjusted to pH 7 with NaOH. Subsequently, cells
were washed twice with PBS and incubated for 24 h with 1, 5 or
15 µmol/l OTA in FCS-free medium. Two or three independent
replicates were performed in triplicate.
Determination of cellular glutathione levels
Total cellular GSH content was determined by the method of Griffith
with minor modifications (GRIFFITH, 1980). HepG2 cells were grown
at a density of 9 x 105 cells per well in 6-well plates for 48 hours and
incubated with OTA, BSO, or NAC at increasing concentrations. After
24 h, the incubation medium was aspirated; cells were washed with
PBS and harvested by trypsination. Due to the limited cell material,
cells of three wells were pooled together. Cell pellets were collected
after centrifugation and stored immediately at -80°C. To measure
glutathione concentrations, cell pellets were resuspended in lysis
buffer (PBS, 0.05% Triton-X (w/v), 0.05 mmol/l EDTA) and homo-
genized. The cell suspension was treated with an equal volume of
10% sulfosalicylic acid (w/v) and separated by centrifugation
(12,000 x g, 5 min, 4°C). 270 µL of the supernatant was mixed
with 20 µL of a 150 mmol/l phosphate buffer (including 1% bovine
serum albumin, pH 7.5) and 30 µL triethanolamin (50%). Sample
(75 µL) was added to the reaction mixture containing 350 µL of
0.28 mmol/l NADPH and 50 µL of 6 mmol/l DTNB (5-5'dithio-bis-
2-nitro-benzoic acid). The reaction was started by addition of 50 µl
glutathione-reductase (10 U/ml) and the increase in absorption at
412 nm was followed for 180 min in 20 sec intervals. Each sample
was measured in duplicate. Results were calculated by comparison
of the difference in absorbance per minute with data from a standard
curve generated with oxidised glutathione. The protein content of
the cell suspension was determined with the commercially available
BCA Protein Kit from Pierce. Three independent replicates were
performed in duplicate.
Statistical analysis
Data are presented as mean with standard deviation. The statistical
program SPSS (version 13.0) was used to assess the effects of various
treatments by analysis of variance (ANOVA) followed by the post
hoc test Dunnett. In the case of inhomogeneous variances multiple
t-tests were applied. Differences were considered significant if
p < 0.05.
Results
Cytotoxicity of OTA
Incubation of HepG2 cells with concentrations of OTA ranging from
0.25 to 50 µmol/l for 24 h resulted in a dose-dependent decline in
cell viability (Fig. 3). Decreasing FCS concentrations were paralleled
by a marked increase in OTA-induced cytotoxicity, with the strongest
effects at OTA concentrations between 0.25 and 15 µmol/l. In cells
cultured in serum-free medium the strongest cytotoxicity was
observed at OTA concentrations between 10 (100% viability) and
250 nmol/l (53% viability). However, in medium containing 5 or 10%
serum, 24 h exposure to 1 µmol/l OTA did not lead to cell death at
all, while 0 or 2.5% serum decreased cell viability to 52 and 87%,
respectively. The minimum level of cell viability (approximately
40%) was reached upon incubation with 15 µmol/l OTA and did not
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decrease further even upon incubation with as much as 50 µmol/l
OTA in FCS-free medium (Fig. 3).The highest non-toxic OTA
concentration was 10 nmol/l (Fig. 4). Due to the higher bioavailability
of OTA under these conditions, serum-free medium was chosen for
further experiments.
Pre-incubation experiments with antioxidants and
glutathione-modulators
A 24 h pre-incubation of HepG2 cells with α-TOC, α-TOC-P, EGCG,
QUE, CAT, and ROSAC at concentrations of 25, 50, or 100 µmol/l
and a subsequent incubation with 1, 5, or 15 µmol/l OTA for 24 h did
not prevent the cytotoxic effects of OTA (Fig. 5). Treatment with α-
TOC-P, EGCG, and QUE even enhanced OTA cytotoxicity dose-
dependently. No changes in cell viability were observed upon pre-
Fig. 2: Chemical structures of the antioxidants
α-Tocopherol Catechin
α-Tocopherol phosphate (disodium salt) Epigallocatechin gallate
Rosmarinic acidQuercetin
Ochratoxin A (µmol/l)
Fig. 3: Influence of foetal calf serum (FCS) concentration on the viability of
HepG2 cells after 24 h incubation with ochratoxin A (0 - 50 µmol/l).
Data are mean ± SD from two experiments in triplicate (n = 6).
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Fig. 4: Viability of HepG2 cells after 24 h incubation with ochratoxin A
(0 - 1000 nmol/l). Data are mean ± SD from two experiments in tri-
plicate (n = 6).
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incubation with α-TOC, CAT and ROSAC. Cellular α-TOC levels
remained unchanged in response to OTA treatment (data not shown),
cellular concentrations of EGCG, QUE, CAT, and ROSAC were not
determined.
To further investigate the involvement of cellular glutathione levels
in OTA-induced cytotoxicity, additional pre-incubations with the
glutathione modulators BSO and NAC were carried out. Incubation
with NAC did not protect OTA-treated cells from cytotoxicity
(Fig. 6A). Pre-incubation with 500 µmol/l BSO decreased cell
viability by 10%, while lower concentrations of BSO were without
effect (Fig. 6B).
Effect on cellular glutathione levels
As shown in Fig. 7A, incubation with BSO for 24 h resulted in a
substantial and dose-dependent depletion of cellular glutathione levels
in HepG2 cells. Concentrations as low as 5 µM decreased cellular
GSH by about 40% compared to untreated controls. A complete GSH-
depletion was observed at 100 µmol/l BSO. Supplementation with
NAC did not increase cellular GSH (data not shown).
Incubation with OTA decreased GSH levels at concentrations of
> 0.25 µmol/l (Fig. 7B). 1 µmol/l OTA led to an approximately 30%
decrease in cellular GSH as compared to controls. In contrast, lower
concentrations (0.05 or 0.1 µmol/l) of OTA resulted in a moderate
increase in GSH levels in HepG2 cells.
Discussion
In line with previous studies our data indicate that OTA induces
cytotoxicity in HepG2 cells in a dose-dependent manner (BALDI
et al., 2004; RENZULLI et al., 2004; HUNDHAUSEN et al., 2005). More-
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Fig. 5: Cytotoxicity of ochratoxin A (24 h, 1 - 15 µmol/l) in HepG2 cells after pre-incubation with RRR-α-tocopherol (α-TOC), RRR-α-tocopherolphosphate,
epigallocatechin gallate (EGCG), quercetin (QUE), catechin (CAT), and rosmarinic acid (ROSAC) (24 h, 0     , 25     , 50     , and 100      µmol/l). Data
are mean ± SD from two experiments in triplicate (n = 6). *Indicates significant differences when compared to control (p < 0.05).
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Fig. 7: Total glutathione (GSH, in % of control) after 24 h incubation with
buthionine sulfoximine (BSO, A) or ochratoxin A (OTA, B) at the
given concentrations. Data are mean ± SD from two experiments in
duplicate (n = 4, A) or triplicate (n = 6, B). *Indicates significant
differences when compared to control (p < 0.05).
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over, we demonstrated a strong impact of serum protein concentration
in the cell culture medium on the viability of OTA-exposed HepG2
cells. A decrease in serum concentration led to a dramatic increase
in OTA-induced cell death in HepG2 cells. Importantly, under serum-
free conditions even nanomolar OTA-concentrations resulted in a
considerable loss of cell viability.
Concerning the protein binding properties of OTA, a high affinity of
OTA for plasma proteins, both in animals and in humans, has been
reported (RINGOT et al., 2006). In a wide range of species, including
quail, mouse, rat and monkey, the fraction of free OTA in plasma
was found to be less than 0.2% (HAGELBERG et al., 1989). Further-
more, it is well-known that OTA toxicity depends on its half-life in
the body (O’BRIEN and DIETRICH, 2005), which in turn has been
suggested to be influenced by binding of OTA to proteins (CHU,
1971; CHU, 1974). This is supported by findings that albumin-
deficient rats had a 20- to 70-times faster OTA clearance from the
systemic circulation than non-deficient rats (KUMAGAI, 1985).
However, studies investigating the dose-response relationship
between the protein concentration in the cell culture medium and
OTA toxicity are lacking. For this reason, a major focus of the present
study was to determine the impact of different FCS levels in the
culture medium on OTA-induced cell death in hepatocytes. We
observed that a decrease of serum concentration in the medium was
paralleled by a dramatic increase in OTA toxicity, which may indicate
strong protein binding of OTA, possibly linked with inhibited cellular
uptake and, thus, lower toxicity in HepG2 cells. Consistently, a
previous study revealed decreased neurotoxic effects of OTA by
protein binding to bovine serum albumin in embryonic chick brain
and neural retina cell cultures (BRUININK and SIDLER, 1997). On the
other hand, protein binding alone does not always decrease OTA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Cytotoxicity of ochratoxin A (24 h, 1 - 15 µmol/l) on HepG2 cells after pre-incubation 
with N-acetylcysteine (NAC, A) (24 h, 0 - 4 mmol/l) or buthionine sulfoximine (BSO, 
B) (24 h, 0 – 500 µmol/l). Data are mean ± SD from two experiments in triplicate (n 
= 6).*Indicates significant differences when compared to control (Dunnett; p < 0.05). 
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Fig. 6: Cytotoxicity of ochratoxin A (24 h, 1 -15 µmol/l) on HepG2 cells after
pre-incubation with N-acetylcysteine (NAC, A) (24 h, 0 - 4 mmol/l)
or buthionine sulfoximine (BSO, B) (24 h, 0 - 500 µmol/l). Data are
mean ± SD fr m two experiments in triplicate (n = 6). *Indicates
significant differences when compared to control (Dunnett; p < 0.05).
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toxicity (STOJKOVIC et al., 1984). It has been suggested that binding
of OTA to two small serum proteins (molecular mass 20.000 Da),
being able to pass through the glomerular membrane, might explain
the OTA-mediated nephrotoxic effect in mammals (STOJKOVIC et al.,
1984).
Taken together, variations in the degree of protein binding as well as
selective binding of OTA to distinct proteins may contribute to the
often reported species-specific differences in OTA toxicity (DIETRICH
et al., 2001; O’BRIEN et al., 2001; HEUSSNER et al., 2002).
In the present study, we investigated the potential cytotoxic effects
of OTA at nanomolar concentrations. Previous studies have revealed
that nanomolar OTA concentrations induced damage to renal and
brain cells, due to an induction of apoptosis (GEKLE et al., 2000) and
a loss of neuronal enzyme activity (MONNET-TSCHUDI et al., 1997).
Our study, however, is the first to demonstrate that OTA causes cell
death in hepatocytes at nanomolar concentrations, which is probably
due to the absence of foetal calf serum (FCS) in the culture medium.
Under serum-free conditions, incubation with 50, 100, or 250 nmol/l
OTA for 24 hours resulted in an approximately 10, 40, or 60%
decrease in viability of HepG2 cells, respectively. We observed
toxicity with concentrations as low as 50 nmol/l OTA, which is with-
in the range of OTA detected in human blood and serum. Between
6 and 26% of human blood and serum samples from the Balkan area
contained OTA in the range of 1 - 35 ng/ml (2.5 - 88 nmol/l) and
1 - 40 ng/ml (2.5 - 100 nmol/l) (PETKOVA-BOCHAROVA et al., 1988),
respectively, paralleled by an increased occurrence of the Balkan
Endemic Nephropathie (BEN) (PETKOVA-BOCHAROVA et al., 1988).
Considering the elimination half-life of OTA in humans of approxi-
mately 36 days (STUDER-ROHR et al., 2000), which is substantially
longer than that reported for other species – mice 40 h; rats 55-120 h
(GALTIER et al., 1979; HAGELBERG et al., 1989); pigs 72-120 h
(GALTIER et al., 1981); monkeys 820 h (KUIPER-GOODMAN and SCOTT,
1989) – it is apparent that OTA constitutes a higher risk in humans.
Our study also demonstrated that at least 45% of the cells were still
viable after incubation with 50 µmol/l OTA for 24 h. In serum-free
medium this maximum toxicity was reached at OTA concentrations
as low as 0.25 µmol/l. Incubation with 1 - 50 µmol/l OTA did not
further increase OTA-induced cell death in HepG2 cells. In ac-
cordance with our results it has been shown in LLC-PK1 cells that
higher OTA-concentrations (high nmol/l to low µmol/l) or longer
times of exposure (96 h) did not further decrease cell viability
(DREGER et al., 2000). One hypothesis, which might explain the
survival of a considerable number of HepG2 cells, suggests the
existence of OTA carrier systems being saturated at low OTA-
concentrations and, thus, not being able to increase intracellular
OTA-transport at higher OTA-concentrations. Such OTA carriers,
belonging to the family of human organic anion transporters, are
well-known in proximal tubule cells from mice (JUNG et al., 2001;
BABU et al., 2002). However, studies investigating the transport of
OTA in liver cells are rare. It has been proposed, however, that the
organic anion-transporting polypeptide (OATP) is involved in OTA-
uptake in hepatocytes (KONTAXI et al., 1996).
Neither the toxicokinetics of OTA, nor its precise toxicity mecha-
nisms have been established to date. Nevertheless, the involvement
of reactive oxygen species (ROS) in OTA toxicity seems to be likely
(RAHIMTULA et al., 1988; GAUTIER et al., 2001; SCHAAF et al., 2002).
Therefore, one objective of our study was to counteract OTA toxicity
by pre-incubation of HepG2 cells with various antioxidant test
substances. We pre-incubated liver cells with 25, 50, or 100 µmol/l
of the respective antioxidants. Concerning α-TOC these concen-
trations are similar to physiological plasma concentrations, which
have been reported in the range of 25 - 40 µmol/l (HENSLEY et al.,
2004), referring to flavonoid concentrations used in the cell culture
experiments however exceeded physiological plasma concentrations
(0.1 - 10 µmol/l) (MANACH et al., 2004). To avoid interactions between
OTA and the test compounds in the culture medium, cells were
washed twice with PBS before incubation with OTA. None of the
test compounds prevented HepG2 cells from OTA-induced cell death.
This is in contrast to studies reporting protective effects of anti-
oxidants towards OTA-induced cell damage. For example, 24 h of
pre-treatment with 50 µmol/l cyanidin-3-O-beta-glucopyranoside or
50 µmol/l rosmarinic acid inhibited the cytotoxicity of 10 µmol/l
OTA in HepG2 cells by 25 and 35%, respectively (RENZULLI et al.,
2004; GUERRA et al., 2005). Another experiment, also using OTA in
serum-free medium, showed that three hours of pre-incubation with
1 nM α-TOC decreased OTA-induced cytotoxicity in bovine mam-
mary epithelium cells by 10% (BALDI et al., 2004). The reasons for
these conflicting results remain unclear, although cell-specific dif-
ferences might be one plausible explanation.
We also found that EGCG, QUE, and α-TOC-P enhanced the toxic
effects of OTA. α-TOC-P inhibits cell proliferation (OGRU et al., 2004)
and modulates membrane fluidity (REZK et al., 2004). The latter might
be the reason for a facilitated uptake of OTA into HepG2 cells, and
thus, for the observed synergistic toxic effects of α-TOC-P and OTA.
Moreover, it has been demonstrated that both EGCG and QUE are
able to exert not only antioxidant, but also pro-oxidant activity, partly
due to the formation of hydrogen peroxide (METODIEWA et al., 1999;
ELBLING et al., 2005; FERRARESI et al., 2005), which might explain
the increased cytotoxicity of OTA in HepG2 cells.
We further investigated the importance of the intracellular anti-
oxidant glutathione for the prevention of OTA toxicity. Several studies
report a depletion of glutathione by buthionine sulfoximine (BSO),
often paralleled by either loss of cell viability or increased suscepti-
bility to compounds exerting oxidative stress (WRIGHT et al., 1998;
ANDERSON et al., 1999; LONG et al., 2000; ANDERSON and REYNOLDS,
2002; HONDA et al., 2004). However, it has been shown that HepG2
cells are able to survive BSO treatment, which may be explained by
an up-regulation of Bcl-2, a protein preventing apoptosis (D’ALESSIO,
2004). In the present study we confirmed the resistance of HepG2
cells to BSO treatment and showed, additionally, that there were no
synergistic effects of OTA and BSO on cytotoxicity in HepG2 cells.
Although GSH was dose-dependently depleted by both BSO and
OTA (Fig. 7), pre-treatment with BSO did not enhance cell death
(Fig. 6). Furthermore, NAC did not increase cellular GSH levels (data
not shown), and was not able to prevent HepG2 cells against the
toxic effects of OTA (Fig. 6). Consistent with these findings are the
results of a study with cultured rat embryonic cells demonstrating a
decrease of GSH induced by OTA, but no protection due to exogenous
GSH supplementation (HONG et al., 2000). On the other hand, it has
been shown that NAC completely protected LLC-PK1 from OTA-
induced cell death (SCHAAF et al., 2002).
Interestingly, we observed a biphasic effect of OTA on intracellular
GSH levels in HepG2 cells. 50 and 100 nmol/l OTA increased cellular
GSH to 116 and 121% compared to controls, respectively, while OTA
at concentrations between 0.1 and 1 µmol/l dose-dependently de-
creased cellular GSH levels to approximately 70%. This effect may
indicate that GSH is involved in the detoxification of OTA, possibly
by directly binding to OTA as proposed by DAI and co-workers
(2002). On the other hand, it has been shown for brain cells that
OTA-exposure leads to an increased generation of nitric oxide (NO)
(ZURICH et al., 2005), which in turn is detoxified through conjugation
with GSH.
In conclusion, the presented data indicate a dose-dependent effect
of foetal calf serum concentrations in the cell culture medium on
OTA-induced cytotoxicity in HepG2 cells. Supplementation with
dietary antioxidants did not counteract cytotoxic effects of OTA.
Although cellular GSH levels are modulated by OTA, mechanisms
other than oxidative stress are likely to be involved in OTA-induced
cell death in HepG2 cells.
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